Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) Gross Margin (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Gross Margin for 12 consecutive years, with 63.46% as the latest value for Q4 2025.

  • On a quarterly basis, Gross Margin fell 303.0% to 63.46% in Q4 2025 year-over-year; TTM through Dec 2025 was 66.84%, a 74.0% decrease, with the full-year FY2025 number at 69.04%, down 621.0% from a year prior.
  • Gross Margin was 63.46% for Q4 2025 at Aytu Biopharma, down from 66.14% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 77.89% in Q4 2023 to a low of 48.12% in Q2 2021.
  • A 5-year average of 63.27% and a median of 65.2% in 2022 define the central range for Gross Margin.
  • Peak YoY movement for Gross Margin: crashed -1306bps in 2021, then surged 1533bps in 2024.
  • Aytu Biopharma's Gross Margin stood at 53.18% in 2021, then increased by 24bps to 65.81% in 2022, then grew by 18bps to 77.89% in 2023, then decreased by -15bps to 66.49% in 2024, then decreased by -5bps to 63.46% in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Gross Margin are 63.46% (Q4 2025), 66.14% (Q3 2025), and 67.75% (Q2 2025).